Cassava Sciences, Inc. (NASDAQ: SAVA)
$2.3600
+0.0100 ( -0.59% ) 18.8K
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
Market Data
Open
$2.3600
Previous close
$2.3500
Volume
18.8K
Market cap
$113.06M
Day range
$2.3550 - $2.4700
52 week range
$2.2300 - $42.2000
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Dec 03, 2024 |
4 | Insider transactions | 1 | Dec 03, 2024 |
8-k | 8K-related | 15 | Nov 25, 2024 |
4 | Insider transactions | 1 | Nov 20, 2024 |
4 | Insider transactions | 1 | Nov 20, 2024 |
3 | Insider transactions | 2 | Nov 20, 2024 |
3 | Insider transactions | 2 | Nov 20, 2024 |
10-q | Quarterly Reports | 75 | Nov 07, 2024 |
8-k | 8K-related | 15 | Nov 07, 2024 |
8-k | 8K-related | 16 | Oct 08, 2024 |